Literature DB >> 22492899

Multiple drug cost containment policies in Michigan's Medicaid program saved money overall, although some increased costs.

Jennifer Kibicho1, Steven D Pinkerton.   

Abstract

Michigan's Medicaid program implemented four cost containment policies--preferred drug lists, joint and multistate purchasing arrangements, and maximum allowable cost--during 2002-04. The goal was to control growth of drug spending for beneficiaries who were enrolled in both Medicaid and Medicare and taking antihypertensive or antihyperlipidemic prescription drugs. We analyzed the impact of each policy while holding the effect of all other policies constant. Preferred drug lists increased both preferred and generic drugs' market share and reduced daily cost--the cost per day for each prescription provided to a beneficiary. In contrast, the maximum allowable cost policy increased daily cost and was the only policy that did not generate cost savings. The joint and multistate arrangements did not affect daily cost. Despite these policy trade-offs, the cumulative effect was a 10 percent decrease in daily cost and a total cost savings of $46,195 per year. Our findings suggest that policy makers need to evaluate the impact of multiple policies aimed at restraining drug spending, and further evaluate the policy trade-offs, to ensure that scarce public dollars achieve the greatest return for money spent.

Entities:  

Mesh:

Year:  2012        PMID: 22492899      PMCID: PMC4118749          DOI: 10.1377/hlthaff.2011.0246

Source DB:  PubMed          Journal:  Health Aff (Millwood)        ISSN: 0278-2715            Impact factor:   6.301


  12 in total

1.  Segmented regression analysis of interrupted time series studies in medication use research.

Authors:  A K Wagner; S B Soumerai; F Zhang; D Ross-Degnan
Journal:  J Clin Pharm Ther       Date:  2002-08       Impact factor: 2.512

2.  The impact of reference pricing of nonsteroidal anti-inflammatory agents on the use and costs of analgesic drugs.

Authors:  Paul V Grootendorst; John K Marshall; Anne M Holbrook; Lisa R Dolovich; Bernie J O'Brien; Adrian R Levy
Journal:  Health Serv Res       Date:  2005-10       Impact factor: 3.402

3.  Market power and state costs of HIV/AIDS drugs.

Authors:  Arleen A Leibowitz; Neeraj Sood
Journal:  Int J Health Care Finance Econ       Date:  2007-05-05

4.  Impact of two Medicaid prior-authorization policies on antihypertensive use and costs among Michigan and Indiana residents dually enrolled in Medicaid and Medicare: results of a longitudinal, population-based study.

Authors:  Michael R Law; Christine Y Lu; Stephen B Soumerai; Amy Johnson Graves; Robert F LeCates; Fang Zhang; Dennis Ross-Degnan; Alyce S Adams
Journal:  Clin Ther       Date:  2010-04       Impact factor: 3.393

5.  State AIDS Drug Assistance Programs: equity and efficiency in an era of rapidly changing treatment standards.

Authors:  Mira Johri; A David Paltiel; Sue J Goldie; Kenneth A Freedberg
Journal:  Med Care       Date:  2002-05       Impact factor: 2.983

6.  AIDS Drug Assistance Programs: highlighting inequities in human immunodeficiency virus-infection health care in the United States.

Authors:  Rochelle P Walensky; A David Paltiel; Kenneth A Freedberg
Journal:  Clin Infect Dis       Date:  2002-08-02       Impact factor: 9.079

7.  Reference pricing for drugs: is it compatible with U.S. health care?

Authors:  Panos Kanavos; Uwe Reinhardt
Journal:  Health Aff (Millwood)       Date:  2003 May-Jun       Impact factor: 6.301

8.  Trends and current drug utilization patterns of Medicaid beneficiaries.

Authors:  Terry R Lied; Julio Gonzalez; Wendy Taparanskas; Tejas Shukla
Journal:  Health Care Financ Rev       Date:  2006

9.  Utilization and spending trends for antiretroviral medications in the U.S. Medicaid program from 1991 to 2005.

Authors:  Yonghua Jing; Patricia Klein; Christina Ml Kelton; Xing Li; Jeff J Guo
Journal:  AIDS Res Ther       Date:  2007-10-16       Impact factor: 2.250

10.  Medicaid prescription drug spending in the 1990s: a decade of change.

Authors:  David K Baugh; Penelope L Pine; Steve Blackwell; Gary Ciborowski
Journal:  Health Care Financ Rev       Date:  2004
View more
  1 in total

Review 1.  Pharmaceutical policies: effects of reference pricing, other pricing, and purchasing policies.

Authors:  Angela Acosta; Agustín Ciapponi; Morten Aaserud; Valeria Vietto; Astrid Austvoll-Dahlgren; Jan Peter Kösters; Claudia Vacca; Manuel Machado; Diana Hazbeydy Diaz Ayala; Andrew D Oxman
Journal:  Cochrane Database Syst Rev       Date:  2014-10-16
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.